Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 55 | 2024 | 2442 | 8.010 |
Why?
|
Carcinoma, Transitional Cell | 29 | 2024 | 1007 | 4.940 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 11 | 2024 | 346 | 3.670 |
Why?
|
Testicular Neoplasms | 14 | 2024 | 560 | 3.640 |
Why?
|
Urothelium | 17 | 2024 | 264 | 2.780 |
Why?
|
Ureteral Neoplasms | 16 | 2024 | 238 | 2.380 |
Why?
|
Biomarkers, Tumor | 28 | 2024 | 10731 | 1.720 |
Why?
|
Teratoma | 5 | 2023 | 248 | 1.620 |
Why?
|
Kidney Neoplasms | 22 | 2024 | 3116 | 1.570 |
Why?
|
Sarcoma | 5 | 2023 | 1851 | 1.540 |
Why?
|
Adenocarcinoma | 15 | 2023 | 7920 | 1.510 |
Why?
|
Urinary Bladder | 7 | 2021 | 592 | 1.460 |
Why?
|
Oncogene Proteins, Fusion | 5 | 2017 | 796 | 1.370 |
Why?
|
Ureter | 11 | 2023 | 218 | 1.310 |
Why?
|
Carcinoma, Small Cell | 5 | 2018 | 426 | 1.280 |
Why?
|
Neoplasm Invasiveness | 18 | 2024 | 4054 | 1.270 |
Why?
|
Nephroureterectomy | 4 | 2024 | 48 | 1.200 |
Why?
|
BCG Vaccine | 9 | 2024 | 430 | 1.180 |
Why?
|
Immunohistochemistry | 21 | 2024 | 7647 | 1.140 |
Why?
|
Cystectomy | 17 | 2024 | 637 | 1.130 |
Why?
|
Carcinoma | 11 | 2022 | 2609 | 1.080 |
Why?
|
Epithelioid Cells | 2 | 2024 | 45 | 1.030 |
Why?
|
Prostatic Neoplasms | 16 | 2022 | 5870 | 1.010 |
Why?
|
Trophoblastic Neoplasms | 1 | 2024 | 23 | 0.960 |
Why?
|
Mucous Membrane | 4 | 2024 | 258 | 0.950 |
Why?
|
Urologic Neoplasms | 7 | 2024 | 204 | 0.930 |
Why?
|
Disease Progression | 11 | 2024 | 6881 | 0.880 |
Why?
|
Carcinoma, Neuroendocrine | 6 | 2023 | 742 | 0.860 |
Why?
|
Hematuria | 2 | 2019 | 83 | 0.800 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2022 | 36 | 0.780 |
Why?
|
Male | 84 | 2024 | 128520 | 0.750 |
Why?
|
Neoplasm Recurrence, Local | 26 | 2023 | 10409 | 0.740 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2022 | 180 | 0.740 |
Why?
|
GATA3 Transcription Factor | 3 | 2020 | 144 | 0.730 |
Why?
|
Middle Aged | 64 | 2024 | 90569 | 0.720 |
Why?
|
Gene Fusion | 3 | 2011 | 214 | 0.710 |
Why?
|
Aged | 60 | 2024 | 73640 | 0.710 |
Why?
|
Humans | 118 | 2024 | 270804 | 0.700 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 1 | 2019 | 12 | 0.690 |
Why?
|
Muscle, Smooth | 2 | 2020 | 250 | 0.690 |
Why?
|
Epithelial-Mesenchymal Transition | 3 | 2024 | 1002 | 0.680 |
Why?
|
Carcinogenesis | 3 | 2024 | 1033 | 0.660 |
Why?
|
Wilms Tumor | 1 | 2022 | 302 | 0.650 |
Why?
|
Urogenital System | 1 | 2019 | 60 | 0.650 |
Why?
|
Uroplakin II | 2 | 2016 | 15 | 0.630 |
Why?
|
Aged, 80 and over | 32 | 2024 | 31117 | 0.600 |
Why?
|
Adult | 44 | 2024 | 82073 | 0.590 |
Why?
|
Carcinoma, Papillary | 4 | 2021 | 566 | 0.590 |
Why?
|
Seminoma | 6 | 2014 | 86 | 0.580 |
Why?
|
Carcinoma, Squamous Cell | 7 | 2020 | 5606 | 0.570 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2017 | 42 | 0.570 |
Why?
|
DNA Copy Number Variations | 1 | 2024 | 1576 | 0.560 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2017 | 98 | 0.540 |
Why?
|
Adjuvants, Immunologic | 7 | 2024 | 669 | 0.530 |
Why?
|
Kidney Pelvis | 3 | 2017 | 113 | 0.530 |
Why?
|
Neoplasm Grading | 10 | 2024 | 1828 | 0.500 |
Why?
|
Uroplakin III | 1 | 2014 | 8 | 0.490 |
Why?
|
Retrospective Studies | 34 | 2024 | 39982 | 0.490 |
Why?
|
Biopsy | 8 | 2024 | 3490 | 0.460 |
Why?
|
Urinary Tract | 3 | 2023 | 87 | 0.450 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2021 | 557 | 0.450 |
Why?
|
Adenocarcinoma, Follicular | 2 | 2014 | 131 | 0.440 |
Why?
|
Female | 51 | 2024 | 148936 | 0.440 |
Why?
|
Prognosis | 26 | 2024 | 22533 | 0.420 |
Why?
|
Sarcoma, Ewing | 1 | 2017 | 428 | 0.420 |
Why?
|
Carcinosarcoma | 1 | 2014 | 145 | 0.420 |
Why?
|
Nephrectomy | 11 | 2014 | 793 | 0.400 |
Why?
|
Orchiectomy | 4 | 2022 | 211 | 0.390 |
Why?
|
Angiomyolipoma | 2 | 2010 | 30 | 0.390 |
Why?
|
Chondrosarcoma | 1 | 2014 | 213 | 0.390 |
Why?
|
Mutation | 6 | 2024 | 15922 | 0.370 |
Why?
|
Prostatectomy | 7 | 2022 | 1004 | 0.360 |
Why?
|
Fatal Outcome | 4 | 2017 | 818 | 0.360 |
Why?
|
Urogenital Neoplasms | 2 | 2024 | 118 | 0.340 |
Why?
|
Young Adult | 15 | 2024 | 22255 | 0.340 |
Why?
|
Hemangiosarcoma | 2 | 2010 | 238 | 0.330 |
Why?
|
Administration, Intravesical | 4 | 2023 | 171 | 0.330 |
Why?
|
RNA, Messenger | 3 | 2016 | 6344 | 0.330 |
Why?
|
Carcinoma in Situ | 3 | 2016 | 489 | 0.330 |
Why?
|
DNA Mutational Analysis | 3 | 2024 | 2356 | 0.310 |
Why?
|
Carcinoma, Renal Cell | 3 | 2024 | 2394 | 0.300 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2024 | 2312 | 0.300 |
Why?
|
Cisplatin | 7 | 2023 | 2509 | 0.280 |
Why?
|
Transcriptome | 1 | 2016 | 1960 | 0.280 |
Why?
|
Carcinoma, Large Cell | 2 | 2021 | 98 | 0.280 |
Why?
|
Tissue Array Analysis | 4 | 2016 | 757 | 0.270 |
Why?
|
Survival Rate | 16 | 2017 | 12535 | 0.270 |
Why?
|
Bone Neoplasms | 2 | 2017 | 2674 | 0.270 |
Why?
|
Carcinoma, Verrucous | 1 | 2006 | 14 | 0.270 |
Why?
|
Neoplasm Staging | 18 | 2024 | 14037 | 0.270 |
Why?
|
Chorionic Gonadotropin, beta Subunit, Human | 2 | 2024 | 56 | 0.260 |
Why?
|
Endodermal Sinus Tumor | 4 | 2013 | 50 | 0.260 |
Why?
|
Treatment Outcome | 19 | 2024 | 33859 | 0.250 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2024 | 9047 | 0.250 |
Why?
|
Carcinoma, Ductal | 1 | 2006 | 144 | 0.250 |
Why?
|
Combined Modality Therapy | 10 | 2023 | 9054 | 0.240 |
Why?
|
Gene Expression Profiling | 8 | 2020 | 5146 | 0.230 |
Why?
|
ADP-ribosyl Cyclase 1 | 1 | 2024 | 149 | 0.230 |
Why?
|
Cytodiagnosis | 1 | 2024 | 201 | 0.220 |
Why?
|
Neoplasms, Second Primary | 2 | 2022 | 1388 | 0.220 |
Why?
|
Diagnosis, Differential | 5 | 2020 | 4839 | 0.220 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2024 | 1536 | 0.210 |
Why?
|
World Health Organization | 1 | 2024 | 321 | 0.210 |
Why?
|
Organ Sparing Treatments | 1 | 2024 | 283 | 0.200 |
Why?
|
Tertiary Care Centers | 1 | 2024 | 419 | 0.200 |
Why?
|
Gene Rearrangement | 2 | 2019 | 809 | 0.200 |
Why?
|
Folic Acid Antagonists | 1 | 2022 | 48 | 0.200 |
Why?
|
Lymphatic Metastasis | 11 | 2014 | 4969 | 0.200 |
Why?
|
Mycobacterium bovis | 1 | 2022 | 68 | 0.200 |
Why?
|
Synaptophysin | 2 | 2011 | 83 | 0.190 |
Why?
|
Transgender Persons | 1 | 2022 | 62 | 0.190 |
Why?
|
Genomics | 3 | 2022 | 2834 | 0.190 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2024 | 3656 | 0.190 |
Why?
|
Sensitivity and Specificity | 4 | 2020 | 5157 | 0.180 |
Why?
|
Telomerase | 1 | 2024 | 544 | 0.180 |
Why?
|
Neoplasm Metastasis | 7 | 2017 | 5332 | 0.180 |
Why?
|
Keratin-6 | 1 | 2020 | 40 | 0.180 |
Why?
|
Keratin-5 | 1 | 2020 | 57 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 7 | 2018 | 6259 | 0.180 |
Why?
|
Patient Selection | 3 | 2024 | 2032 | 0.180 |
Why?
|
Rectal Neoplasms | 1 | 2009 | 1240 | 0.180 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2021 | 298 | 0.180 |
Why?
|
Pathology | 1 | 2021 | 102 | 0.170 |
Why?
|
Antibodies, Monoclonal | 2 | 2024 | 4470 | 0.170 |
Why?
|
Leiomyosarcoma | 3 | 2010 | 253 | 0.170 |
Why?
|
Down-Regulation | 2 | 2016 | 2087 | 0.170 |
Why?
|
Databases, Genetic | 2 | 2020 | 758 | 0.170 |
Why?
|
Adolescent | 8 | 2022 | 32698 | 0.160 |
Why?
|
MicroRNAs | 3 | 2019 | 2883 | 0.160 |
Why?
|
Cell Differentiation | 2 | 2024 | 4102 | 0.160 |
Why?
|
Urology | 1 | 2020 | 140 | 0.160 |
Why?
|
Immunotherapy | 4 | 2021 | 3561 | 0.160 |
Why?
|
Carcinoma, Embryonal | 3 | 2013 | 31 | 0.160 |
Why?
|
Androgen Antagonists | 2 | 2022 | 420 | 0.160 |
Why?
|
Pathologists | 1 | 2019 | 101 | 0.150 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 66 | 0.150 |
Why?
|
Lymph Node Excision | 6 | 2014 | 2068 | 0.150 |
Why?
|
Mutagenesis | 1 | 2019 | 509 | 0.150 |
Why?
|
Texas | 4 | 2018 | 6445 | 0.150 |
Why?
|
Follow-Up Studies | 8 | 2017 | 15280 | 0.140 |
Why?
|
Whole Genome Sequencing | 2 | 2017 | 367 | 0.140 |
Why?
|
Neoadjuvant Therapy | 5 | 2022 | 5247 | 0.140 |
Why?
|
Clonal Evolution | 1 | 2019 | 250 | 0.140 |
Why?
|
Chromosome Deletion | 1 | 2021 | 1057 | 0.140 |
Why?
|
Disease-Free Survival | 11 | 2021 | 10268 | 0.140 |
Why?
|
Neoplasms, Basal Cell | 1 | 2016 | 32 | 0.140 |
Why?
|
RNA-Binding Proteins | 2 | 2013 | 1016 | 0.140 |
Why?
|
Muscle Neoplasms | 1 | 2017 | 108 | 0.140 |
Why?
|
Keratin-14 | 1 | 2016 | 24 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 7 | 2021 | 4007 | 0.130 |
Why?
|
Nanomedicine | 1 | 2016 | 53 | 0.130 |
Why?
|
ATPases Associated with Diverse Cellular Activities | 1 | 2016 | 86 | 0.130 |
Why?
|
Lung Neoplasms | 4 | 2014 | 12045 | 0.130 |
Why?
|
Cell Transdifferentiation | 1 | 2017 | 114 | 0.130 |
Why?
|
Multigene Family | 1 | 2017 | 469 | 0.130 |
Why?
|
Aurora Kinase A | 1 | 2017 | 209 | 0.130 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 1404 | 0.130 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2017 | 347 | 0.120 |
Why?
|
Survival Analysis | 4 | 2020 | 9281 | 0.120 |
Why?
|
Gene Silencing | 1 | 2018 | 825 | 0.120 |
Why?
|
Prostate-Specific Antigen | 4 | 2012 | 1030 | 0.120 |
Why?
|
Hyaluronan Receptors | 1 | 2016 | 247 | 0.120 |
Why?
|
PPAR gamma | 1 | 2016 | 224 | 0.120 |
Why?
|
Gene Regulatory Networks | 1 | 2019 | 679 | 0.120 |
Why?
|
Plasmids | 1 | 2016 | 923 | 0.110 |
Why?
|
Urethral Neoplasms | 1 | 2014 | 62 | 0.110 |
Why?
|
Liposomes | 1 | 2016 | 708 | 0.110 |
Why?
|
Receptor, ErbB-2 | 1 | 2024 | 2659 | 0.110 |
Why?
|
Virus Integration | 1 | 2014 | 73 | 0.110 |
Why?
|
Liver Neoplasms | 1 | 2011 | 4843 | 0.110 |
Why?
|
HSP72 Heat-Shock Proteins | 1 | 2013 | 14 | 0.110 |
Why?
|
Transcription, Genetic | 2 | 2019 | 3328 | 0.110 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3054 | 0.110 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 5099 | 0.110 |
Why?
|
DNA Helicases | 1 | 2016 | 459 | 0.110 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 4966 | 0.110 |
Why?
|
Retroperitoneal Space | 1 | 2013 | 156 | 0.110 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 866 | 0.110 |
Why?
|
Societies, Medical | 1 | 2019 | 1323 | 0.100 |
Why?
|
Hyperplasia | 2 | 2022 | 571 | 0.100 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2020 | 1338 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 5779 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2017 | 637 | 0.100 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1011 | 0.100 |
Why?
|
Practice Patterns, Physicians' | 1 | 2020 | 1301 | 0.100 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2017 | 841 | 0.100 |
Why?
|
Prostatic Intraepithelial Neoplasia | 2 | 2014 | 81 | 0.100 |
Why?
|
Chromogranins | 1 | 2011 | 87 | 0.100 |
Why?
|
Acid Phosphatase | 1 | 2011 | 56 | 0.100 |
Why?
|
Boronic Acids | 1 | 2013 | 355 | 0.100 |
Why?
|
Oncogene Fusion | 1 | 2011 | 62 | 0.100 |
Why?
|
Translocation, Genetic | 1 | 2017 | 1286 | 0.090 |
Why?
|
Phenotype | 2 | 2020 | 6503 | 0.090 |
Why?
|
Chromogranin A | 1 | 2011 | 67 | 0.090 |
Why?
|
Kidney | 3 | 2021 | 2102 | 0.090 |
Why?
|
Cell Death | 1 | 2013 | 685 | 0.090 |
Why?
|
DNA Methylation | 2 | 2019 | 2769 | 0.090 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2011 | 109 | 0.090 |
Why?
|
Keratins | 1 | 2011 | 340 | 0.090 |
Why?
|
Case-Control Studies | 1 | 2020 | 6234 | 0.090 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2011 | 189 | 0.090 |
Why?
|
Viscera | 1 | 2010 | 88 | 0.090 |
Why?
|
Neuroendocrine Tumors | 1 | 2017 | 656 | 0.090 |
Why?
|
Pyrazines | 1 | 2013 | 511 | 0.090 |
Why?
|
Lymph Nodes | 2 | 2013 | 3081 | 0.090 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 3841 | 0.090 |
Why?
|
Multimodal Imaging | 1 | 2014 | 551 | 0.090 |
Why?
|
Biopsy, Needle | 2 | 2021 | 1381 | 0.090 |
Why?
|
Protein Kinases | 1 | 2014 | 889 | 0.080 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 690 | 0.080 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 271 | 0.080 |
Why?
|
ErbB Receptors | 2 | 2009 | 2376 | 0.080 |
Why?
|
Transcription Factors | 2 | 2016 | 5415 | 0.080 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2020 | 3429 | 0.080 |
Why?
|
Leiomyoma | 1 | 2010 | 162 | 0.080 |
Why?
|
Transplantation, Heterologous | 1 | 2010 | 1054 | 0.080 |
Why?
|
Chromatin | 1 | 2014 | 1041 | 0.080 |
Why?
|
Positron-Emission Tomography | 2 | 2014 | 2199 | 0.080 |
Why?
|
Time Factors | 3 | 2017 | 12979 | 0.080 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 1342 | 0.080 |
Why?
|
Cell Nucleus | 3 | 2010 | 1715 | 0.080 |
Why?
|
Image-Guided Biopsy | 2 | 2021 | 336 | 0.080 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2014 | 1260 | 0.080 |
Why?
|
Cell Cycle | 1 | 2014 | 2135 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 1902 | 0.070 |
Why?
|
Carcinoid Tumor | 1 | 2010 | 282 | 0.070 |
Why?
|
Biopsy, Fine-Needle | 1 | 2011 | 690 | 0.070 |
Why?
|
Carrier Proteins | 1 | 2016 | 2084 | 0.070 |
Why?
|
Neoplasm Transplantation | 1 | 2010 | 1553 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5417 | 0.070 |
Why?
|
Oxidative Stress | 1 | 2014 | 1152 | 0.070 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2014 | 1704 | 0.070 |
Why?
|
Molecular Targeted Therapy | 2 | 2016 | 2396 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 2050 | 0.070 |
Why?
|
Condylomata Acuminata | 1 | 2006 | 32 | 0.070 |
Why?
|
Health Surveys | 2 | 2020 | 395 | 0.070 |
Why?
|
Child | 4 | 2017 | 30572 | 0.070 |
Why?
|
Mediastinal Neoplasms | 1 | 2010 | 428 | 0.060 |
Why?
|
Quinazolines | 1 | 2011 | 956 | 0.060 |
Why?
|
Animals | 5 | 2024 | 61362 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 16751 | 0.060 |
Why?
|
Prostate | 1 | 2010 | 1090 | 0.060 |
Why?
|
Nuclear Proteins | 2 | 2019 | 3435 | 0.060 |
Why?
|
In Situ Hybridization | 1 | 2006 | 1043 | 0.060 |
Why?
|
Ureteroscopy | 1 | 2024 | 51 | 0.060 |
Why?
|
Trans-Activators | 1 | 2010 | 1626 | 0.060 |
Why?
|
Cluster Analysis | 2 | 2017 | 1076 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 3 | 2016 | 7789 | 0.060 |
Why?
|
Receptors, Lysophosphatidic Acid | 1 | 2024 | 89 | 0.060 |
Why?
|
Necrosis | 3 | 2010 | 591 | 0.060 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2024 | 67 | 0.060 |
Why?
|
Disease Models, Animal | 1 | 2017 | 7323 | 0.060 |
Why?
|
Signal Transduction | 3 | 2021 | 12036 | 0.060 |
Why?
|
Salvage Therapy | 1 | 2012 | 2124 | 0.060 |
Why?
|
Mitosis | 3 | 2010 | 681 | 0.050 |
Why?
|
Melanoma | 1 | 2020 | 5601 | 0.050 |
Why?
|
Laparoscopy | 2 | 2009 | 1304 | 0.050 |
Why?
|
Papillomaviridae | 1 | 2006 | 636 | 0.050 |
Why?
|
Risk Factors | 5 | 2021 | 17867 | 0.050 |
Why?
|
Pilot Projects | 2 | 2024 | 2855 | 0.050 |
Why?
|
Gender Identity | 1 | 2022 | 80 | 0.050 |
Why?
|
Survivorship | 1 | 2022 | 116 | 0.050 |
Why?
|
Piperazines | 1 | 2011 | 2143 | 0.050 |
Why?
|
Atrophy | 1 | 2022 | 271 | 0.050 |
Why?
|
Terminology as Topic | 1 | 2024 | 414 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2010 | 3930 | 0.050 |
Why?
|
Hormones | 1 | 2022 | 284 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2010 | 2618 | 0.050 |
Why?
|
Phenylurea Compounds | 1 | 2024 | 600 | 0.040 |
Why?
|
alpha-Fetoproteins | 2 | 2013 | 256 | 0.040 |
Why?
|
Risk Assessment | 3 | 2021 | 6766 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2024 | 1091 | 0.040 |
Why?
|
Child, Preschool | 2 | 2013 | 17083 | 0.040 |
Why?
|
Immune Tolerance | 1 | 2021 | 434 | 0.040 |
Why?
|
Homozygote | 1 | 2021 | 771 | 0.040 |
Why?
|
Glomerular Filtration Rate | 1 | 2022 | 589 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2021 | 333 | 0.040 |
Why?
|
Mice | 3 | 2024 | 35420 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2023 | 1389 | 0.040 |
Why?
|
Sequence Analysis, Protein | 1 | 2017 | 80 | 0.040 |
Why?
|
Snail Family Transcription Factors | 1 | 2017 | 119 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 326 | 0.040 |
Why?
|
Prospective Studies | 2 | 2022 | 13422 | 0.030 |
Why?
|
Receptors, Transferrin | 1 | 2016 | 41 | 0.030 |
Why?
|
Mutation Rate | 1 | 2017 | 220 | 0.030 |
Why?
|
Vinblastine | 1 | 2017 | 462 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2017 | 14885 | 0.030 |
Why?
|
CTLA-4 Antigen | 1 | 2020 | 679 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1033 | 0.030 |
Why?
|
Consensus | 1 | 2021 | 1113 | 0.030 |
Why?
|
Single-Chain Antibodies | 1 | 2016 | 61 | 0.030 |
Why?
|
United States | 4 | 2018 | 15834 | 0.030 |
Why?
|
Retinoblastoma Protein | 1 | 2016 | 339 | 0.030 |
Why?
|
B7-H1 Antigen | 1 | 2021 | 1098 | 0.030 |
Why?
|
Databases, Factual | 1 | 2021 | 2261 | 0.030 |
Why?
|
Transgenes | 1 | 2016 | 568 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 7923 | 0.030 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2020 | 1096 | 0.030 |
Why?
|
Methotrexate | 1 | 2017 | 1025 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2017 | 674 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2012 | 4320 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2014 | 374 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2014 | 128 | 0.030 |
Why?
|
Bone Morphogenetic Protein 2 | 1 | 2013 | 123 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2014 | 219 | 0.030 |
Why?
|
Gene Transfer Techniques | 1 | 2016 | 800 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 7054 | 0.030 |
Why?
|
Antineoplastic Agents | 5 | 2016 | 14639 | 0.030 |
Why?
|
Observer Variation | 1 | 2014 | 709 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2013 | 396 | 0.030 |
Why?
|
Glutathione Transferase | 1 | 2013 | 364 | 0.030 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2013 | 506 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2014 | 6193 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2017 | 1105 | 0.020 |
Why?
|
Immunoblotting | 1 | 2013 | 887 | 0.020 |
Why?
|
Bortezomib | 1 | 2013 | 551 | 0.020 |
Why?
|
Pyrimidines | 1 | 2024 | 3671 | 0.020 |
Why?
|
Preoperative Care | 1 | 2017 | 1582 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2013 | 843 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2012 | 448 | 0.020 |
Why?
|
DNA Primers | 1 | 2013 | 1489 | 0.020 |
Why?
|
Computational Biology | 1 | 2017 | 1295 | 0.020 |
Why?
|
Pancreatic Neoplasms | 1 | 2008 | 5264 | 0.020 |
Why?
|
Genome, Human | 1 | 2019 | 1896 | 0.020 |
Why?
|
Choriocarcinoma | 1 | 2010 | 49 | 0.020 |
Why?
|
Sialoglycoproteins | 1 | 2010 | 149 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2013 | 1072 | 0.020 |
Why?
|
Peritoneum | 1 | 2011 | 151 | 0.020 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2010 | 105 | 0.020 |
Why?
|
Doxorubicin | 1 | 2017 | 3147 | 0.020 |
Why?
|
Chile | 1 | 2009 | 69 | 0.020 |
Why?
|
Giant Cells | 1 | 2010 | 73 | 0.020 |
Why?
|
Antigens, Surface | 1 | 2010 | 304 | 0.020 |
Why?
|
Proteoglycans | 1 | 2010 | 278 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2013 | 1195 | 0.020 |
Why?
|
Japan | 1 | 2009 | 240 | 0.020 |
Why?
|
Ki-1 Antigen | 1 | 2010 | 186 | 0.020 |
Why?
|
Cell Count | 1 | 2010 | 509 | 0.020 |
Why?
|
Cell Movement | 1 | 2017 | 2468 | 0.020 |
Why?
|
North America | 1 | 2009 | 337 | 0.020 |
Why?
|
Spermatozoa | 1 | 2011 | 292 | 0.020 |
Why?
|
Urologic Surgical Procedures | 1 | 2009 | 93 | 0.020 |
Why?
|
Research Design | 1 | 2016 | 1562 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 1345 | 0.020 |
Why?
|
Genetic Therapy | 1 | 2016 | 1715 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2010 | 485 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 249 | 0.020 |
Why?
|
Europe | 1 | 2009 | 650 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2014 | 1761 | 0.020 |
Why?
|
Contrast Media | 1 | 2014 | 1505 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 3582 | 0.020 |
Why?
|
Drug Therapy | 1 | 2007 | 205 | 0.020 |
Why?
|
Mice, SCID | 1 | 2010 | 1825 | 0.020 |
Why?
|
Rhabdomyosarcoma | 1 | 2010 | 342 | 0.020 |
Why?
|
Physicians | 1 | 2014 | 854 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2011 | 3533 | 0.020 |
Why?
|
Chemoradiotherapy | 1 | 2014 | 2038 | 0.020 |
Why?
|
Sex Factors | 1 | 2010 | 2180 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2017 | 7233 | 0.010 |
Why?
|
Cohort Studies | 1 | 2016 | 9464 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2454 | 0.010 |
Why?
|
Thyroid Neoplasms | 1 | 2014 | 1908 | 0.010 |
Why?
|
Proteins | 1 | 2010 | 2030 | 0.010 |
Why?
|
Radiotherapy | 1 | 2007 | 1858 | 0.010 |
Why?
|
Neoplasms | 1 | 2021 | 15951 | 0.010 |
Why?
|
Infant | 1 | 2009 | 14003 | 0.010 |
Why?
|